Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Rahima Jamal is active.

Publication


Featured researches published by Rahima Jamal.


Ndt Plus | 2008

Permanent renal failure induced by pentastarch

Rahima Jamal; Marc Ghannoum; Jean-François Naud; Pierre-Paul Turgeon; Martine Leblanc

Background. Controversy exists with volume resuscitation using crystalloids or colloids. Renal dysfunction has been reported with some colloids and osmotic agents, but remains poorly defined. Patient. We report the case of a 67-year-old male who had normal kidney function at baseline and who developed anuric ARF in relation to the administration of >10 litres of 10% pentastarch. A renal biopsy confirmed hydropic changes in tubular cells compatible with colloid-induced damage. Conclusion. This case demonstrates that hydroxyethyl starch preparations may be associated with acute kidney injury, and one should carefully consider their use, especially in patients with pre-existing renal dysfunction. Osmotic tubular cell lesions may be long lasting and irreversible.


Journal of Clinical Oncology | 2017

Atezolizumab (A) + cobimetinib (C) in metastatic melanoma (mel): Updated safety and clinical activity.

Wilson H. Miller; Tae Min Kim; Carrie B. Lee; Keith T. Flaherty; Sunil Reddy; Rahima Jamal; Laura Q. Chow; Isabelle Rooney; Bethany Pitcher; Edward Cha; Jeffrey R. Infante


Journal of Clinical Oncology | 2017

Safety and clinical activity of first-line durvalumab in advanced NSCLC: Updated results from a Phase 1/2 study.

Scott Antonia; Julie R. Brahmer; Ani Sarkis Balmanoukian; Dong-Wan Kim; Sang-We Kim; Myung-Ju Ahn; Rahima Jamal; Dirk Jaeger; Patrick A. Ott; Paolo Antonio Ascierto; Vanesa Gregorc; Jonathan W. Goldman; Collin M. Blakely; Xiaoping Jin; Joyce Antal; Ashok Kumar Gupta; Neil Howard Segal


Journal for ImmunoTherapy of Cancer | 2017

Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma

Rahima Jamal; Réjean Lapointe; Eftihia Cocolakis; Paméla Thébault; Shirin Kazemi; Jennifer Elisabeth Friedmann; Jeanne Dionne; Jean-François Cailhier; Karl Belanger; Jean-Pierre M. Ayoub; Huy Le; Caroline Lambert; Jida El-Hajjar; Leon Van Kempen; Alan Spatz; Wilson H. Miller


Journal of Clinical Oncology | 2017

A randomized phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM).

Rahima Jamal; Karl Belanger; Jennifer Elisabeth Friedmann; Jean-Pierre M. Ayoub; Eftihia Cocolakis; Shirin Kazemi; Jeanne Dionne; Caroline Lambert; Huy Le; Leon Van Kempen; Alan Spatz; Réjean Lapointe; Wilson H. Miller


Journal of Clinical Oncology | 2017

Updated safety and clinical activity of durvalumab monotherapy in previously treated patients with stage IIIB/IV NSCLC.

Ani Sarkis Balmanoukian; Scott Antonia; Wen-Jen Hwu; Omid Hamid; Martin Gutierrez; Rahima Jamal; Guy Jerusalem; Myung-Ju Ahn; Dong-Wan Kim; David Cunningham; Sang-We Kim; Julie R. Brahmer; Jose Lutzky; Jared Weiss; Xiaoping Jin; Joyce Antal; Ashok Kumar Gupta; Neil Howard Segal


Journal of Clinical Oncology | 2018

Safety and clinical activity of durvalumab monotherapy in patients with gastroesophageal cancers.

Antoine Hollebecque; Zev A. Wainberg; Jaffer A. Ajani; John L. Marshall; David Cunningham; Sai-Hong Ignatius Ou; Jose Lutzky; Rahima Jamal; Giuseppe Curigliano; Martin Gutierrez; John Nemunaitis; Rachel E. Sanborn; Dan Paul Zandberg; Feng Xiao; Natasha Angra; Shaad Essa Abdullah; Neil Howard Segal


Journal of Clinical Oncology | 2018

Systemic immune signature of inflammation in metastatic melanoma (MM) patients treated with ipilimumab (IPI) and carboplatin/paclitaxel (CP).

Wilson H. Miller; Rahima Jamal; Eftihia Cocolakis; Paméla Thébault; Jennifer Elisabeth Friedmann; Shirin Kazemi; Jeanne Dionne; Jean-François Cailhier; Stéphanie Lepage; Karl Belanger; Jean-Pierre M. Ayoub; Huy Le; Caroline Lambert; Jida El Hajjar; Leon Van Kempen; Alan Spatz; Réjean Lapointe


Journal of Clinical Oncology | 2018

Updated overall survival and safety profile of durvalumab monotherapy in advanced NSCLC.

Matthew D. Hellmann; Scott Antonia; Ani Sarkis Balmanoukian; Julie R. Brahmer; Sai-Hong Ignatius Ou; Sang-We Kim; Myung-Ju Ahn; Dong-Wan Kim; Martin Gutierrez; Stephen V. Liu; Patrick Schöffski; Dirk Jaeger; Rahima Jamal; Joseph W. Leach; Guy Jerusalem; Jose Lutzky; John Nemunaitis; Yu Gu; Shaad Essa Abdullah; Neil Howard Segal


Journal of Clinical Oncology | 2017

One-year overall survival (OS) and biomarker correlates from a phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM).

Rahima Jamal; Leon Van Kempen; Paméla Thébault; Karl Belanger; Jennifer Elisabeth Friedmann; Jean-Pierre M. Ayoub; Eftihia Cocolakis; Shirin Kazemi; Jeanne Dionne; Caroline Lambert; Huy Le; Cécile Grange; Jean-François Cailhier; Alan Spatz; Réjean Lapointe; Wilson H. Miller

Collaboration


Dive into the Rahima Jamal's collaboration.

Top Co-Authors

Avatar

Karl Belanger

Université de Montréal

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jeanne Dionne

Université de Montréal

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge